Inebilizumab

Class
Biologic agents
Subclass
Anti-CD19 monoclonal antibodies
Substance name
Inebilizumab, inebilizumab-cdon
Brand names
Uplizna®
Common formulations
Injection
Dosage and administration
Adults patients
Treatment of neuromyelitis optica spectrum disorderAnti-AQP-4 antibody-positive
300 mg IV q6 months
Indications for use
Labeled indications
Adults
Treatment of neuromyelitis optica spectrum disorder (anti-AQP-4 antibody-positive)
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource